Immunogenicity of protein therapeutics: The key causes, consequences and challenges
about
Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune ComplexesBiosimilar insulins: guidance for data interpretation by clinicians and usersMapping the Pareto optimal design space for a functionally deimmunized biotherapeutic candidateComparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc GlycoformsModulating non-native aggregation and electrostatic protein-protein interactions with computationally designed single-point mutationsComputationally driven deletion of broadly distributed T cell epitopes in a biotherapeutic candidate.Protein deimmunization via structure-based design enables efficient epitope deletion at high mutational loadsThe immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.Elimination of murine and human T-cell epitopes in recombinant immunotoxin eliminates neutralizing and anti-drug antibodies in vivo.Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNAQuantitative analysis of the CD4+ T cell response to therapeutic antibodies in healthy donors using a novel T cell:PBMC assayImmunogenicity to biologics: mechanisms, prediction and reduction.A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects.Monoclonal antibody humanness score and its applications.Etanercept biosimilarsBortezomib reduces pre-existing antibodies to recombinant immunotoxins in miceDetection of innate immune response modulating impurities in therapeutic proteinsThe INNs and outs of antibody nonproprietary names.Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society December 7-10, 2015, San Diego, CA, USA.Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.Poor correlation between T-cell activation assays and HLA-DR binding prediction algorithms in an immunogenic fragment of Pseudomonas exotoxin A.Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes.Engineered binding to erythrocytes induces immunological tolerance to E. coli asparaginase.A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicityImmunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophyAnalytical tools for characterizing biopharmaceuticals and the implications for biosimilars.Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.A comparison of biophysical characterization techniques in predicting monoclonal antibody stability.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesMarine Antibody-Drug Conjugates: Design Strategies and Research Progress.Antibody-drug conjugates - a perfect synergy.Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.Monoclonal antibodies for the treatment of osteoporosis.Inhaled biopharmaceutical drug development: nonclinical considerations and case studies.Challenges and approaches for the development of safer immunomodulatory biologics.Preclinical models used for immunogenicity prediction of therapeutic proteins.Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.Frequency Patterns of T-Cell Exposed Amino Acid Motifs in Immunoglobulin Heavy Chain Peptides Presented by MHCsImmunotherapeutic approaches for cancer therapy: An updated review.
P2860
Q26766424-C842461E-60BE-413C-9280-CF2226EA40EEQ26992066-C0A9FC95-6294-471A-ADEC-C1BCE40A2BAFQ28543006-CD710A71-BBC0-42CC-BB00-E379A5D223D5Q28820826-1C0DFBBA-B06B-46D1-B753-F15A145B31FEQ30276839-FF73989E-AB3A-4FB1-90DB-6ED4FA498846Q30363065-5DFD7873-F3B7-4668-BD82-D53841C070E6Q30371474-3EAE796D-59B8-445E-B934-A4D6AF737088Q30995889-3D8778A2-3722-41DD-A8ED-260FC0265D61Q31814859-1A20A226-A276-48AB-84DC-F55F9CE00D39Q33652098-1BF7276C-AAAD-465A-B065-6D9DC24A5BD4Q33652543-9254C184-2784-4F98-A0F5-DA41768F29BEQ33745965-F344BFBC-A54A-42A1-9710-B0E41AF5AE78Q34296526-31C69511-F038-4DD7-8751-B6215F460E57Q34503723-FAFD2E4E-B2B4-4C4F-986C-254E37913DDBQ34798313-9CEB729B-2A0F-4BF9-BC38-45B8E1B76BE4Q35020358-2E02362B-127D-44E7-A8DB-FE8152FD489CQ35070412-6CFBC0D7-130B-4467-A0F3-38D752A231E3Q35611430-311FB512-FE2E-44C0-B381-9C15B7319093Q35881712-C9CC7655-1EFB-43F5-97EA-D23A3267A57DQ35933820-354ED128-0133-4B0D-A64F-7DFA96F250DCQ35967897-B1E0AE07-5BD5-4339-9C3A-6ADDB7BE8AB4Q36157120-71B65F76-1824-40E6-B40D-BD5C3C618756Q36257660-74A825A7-2B0F-40D4-8820-20E7AEDB6400Q36284750-056F45CC-A731-4F19-92BB-249A026E98CBQ36558535-1C4FE5DE-5F66-4ED1-9E64-004F026CF5ADQ36923891-E02A521D-53D7-416F-B117-D9F080A5675DQ37022207-B30B7285-C5DB-40E7-961E-C79A1F9F7788Q37261712-B5FED90F-5655-48F5-8D06-D4665386BA74Q37287010-06243A23-65F2-48FA-AD85-22CB864801A3Q37621530-057D532C-1555-44FA-A5B8-BF57524072FAQ37628646-6CB77B99-92AF-46E6-AEC6-4546ABFA4A0DQ38014923-FEFE99C9-2A6C-4E24-B324-3FBD721156B2Q38048706-4F59F4F7-6354-4977-8534-36759839A30EQ38068600-A73004B5-B203-4CFC-B4CB-FE39FE3D7D6CQ38088303-5AE3A73D-0D46-4648-9516-D012B7410F6BQ38093772-04666A5A-8835-4C15-B9E7-68CEB00F23B6Q38104674-754FAA81-28DA-4419-A1DB-636FC28B791EQ38212929-8F8F3B98-A95B-4D82-A2C2-640C3D161D4BQ38267389-BC024E05-4ECF-4AEA-8EF6-98341D0D3663Q38388102-51FF3430-70D3-4D0D-8D7A-51F4E52621AB
P2860
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
description
2010 nî lūn-bûn
@nan
2010 թուականին հրատարակուած գիտական յօդուած
@hyw
2010 թվականին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@ast
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@en
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@nl
type
label
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@ast
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@en
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@nl
prefLabel
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@ast
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@en
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@nl
P2093
P2860
P3181
P356
P1433
P1476
Immunogenicity of protein therapeutics: The key causes, consequences and challenges
@en
P2093
Brooke Lumicisi
Christine J Bryson
Helen M Reynolds
Matthew P Baker
P2860
P304
P3181
P356
10.4161/SELF.1.4.13904
P407
P577
2010-01-01T00:00:00Z